PKD Research Grants

How does the research grant program work?

Requests for research grant applications are released in the fall of the odd-numbered years (2013, 2015, etc.) and are awarded in February of the following year. Each grant recipient receives $80,000 per year for two years. After the first year of funding, grant recipients submit updates on the progress of their research. After the final year of funding, grant recipients submit the results of their studies in a final report.

2018 Grant recipients

In 2018, we awarded research grants to 15 outstanding PKD researchers. The Research Grant Program will fund critical research to increase understanding of the genetic and pathological processes involved in PKD and to accelerate the development of potential therapies for PKD patients.

Dr. Vincent H. Gattone Research Award

Katharina Hopp, Ph.D.Katharina Hopp, Ph.D.

University of Colorado – Denver

Understanding the role of CD8+ T-cells in halting renal cystogenesis

View summary View bio

Katharina Hopp, Ph.D.Katharina Hopp, Ph.D.

University of Colorado – Denver

Understanding the role of CD8+ T-cells in halting renal cystogenesis

To date research on therapeutics for polycystic kidney disease (PKD) has primarily focused on disrupted pathways in the cystic kidney tubule. However, recent studies in other fields, such as cancer, have shown that cancer cells communicate with their surroundings, and that targeting these communications can alleviate disease. One important cell type within cancers or the cystic kidney surroundings is immune cells. This proposal focuses on a specific immune cell type, T-cells, which we have shown play an important role in keeping cyst growth at bay. Expanding on this observation, we now are examining how T-cells communicate with the cystic tubule and whether targeting this interaction provides a novel therapeutic approach for PKD.

Katharina Hopp, Ph.D.Katharina Hopp, Ph.D.

University of Colorado – Denver

Understanding the role of CD8+ T-cells in halting renal cystogenesis

Dr. Katharina Hopp was born in Germany and came to the U.S.A. for her undergraduate studies. Amid her B.S. she was first exposed to Polycystic Kidney Disease (PKD) research during a summer internship in the laboratory of Dr. Peter C. Harris (Mayo Clinic Rochester MN, U.S.A). Intrigued by the disease’s scientific complexity and the prevalence of PKD patients in need of answers to the many open questions, she pursued her Ph.D. in the laboratory of Dr. Harris studying the genetic complexity associated with the wide spectrum of disease presentation in Autosomal Dominant PKD. After her Ph.D. and post-doctoral studies at the Mayo Clinic Translational PKD Center, she moved to the University of Colorado, Denver to start her own PKD laboratory. Her research focus remained on understanding the disease variability of this common disorder, but she now focuses on the impact of renal immune cells on cyst initiation/progression. Here, she believes that communication between immune cells and cystic tubular cells can influence disease outcome and altering this communication can provide a novel therapeutic target. When Dr. Hopp is not working in the laboratory, she loves hiking through the Rocky Mountains and enjoying outdoor time with her family.

Whitney Besse, M.D.Whitney Besse, M.D.

Yale University

Genetic approach to define mediators of polycystin-1 function in polycystic kidney disease

View summary View bio

Whitney Besse, M.D.Whitney Besse, M.D.

Yale University

Genetic approach to define mediators of polycystin-1 function in polycystic kidney disease

We seek to learn how to compensate for the genetic defect in ADPKD by either increasing the functional amount of the missing proteins or blocking the effects resulting from loss of the mutant proteins. Besides PKD1 and PKD2, many additional human genes are required for the function of the ADPKD proteins. Mutations in these gene can be rare causes of kidney/liver cysts, and study of them can shed light on the pathways we need to target for treatment. This proposal will investigate two such genes, DNAJB11 and PKHD1, in which we identified mutations causing liver/kidney cysts in adults. Excitingly, DNAJB11 is known to have chaperonea function, something that has been upregulated successfully in cystic fibrosis treatment. PKHD1 is the disease gene for ARPKD. We will use mouse models to investigate whether the cysts we see in some carrier parents of ARPKD children suggest that PKHD1 also affects the ADPKD proteins.

Whitney Besse, M.D.Whitney Besse, M.D.

Yale University

Genetic approach to define mediators of polycystin-1 function in polycystic kidney disease

Dr. Besse received her Bachelor of Science degree from Brown University, and medical degree from the University of Connecticut School of Medicine. She obtained her clinical training in both Internal Medicine and Nephrology at the Yale School of Medicine. She began her research in polycystic kidney and liver disease under the mentorship of Dr. Stefan Somlo at Yale. She has made important contributions to the field of PKD research by using genetic approaches to identify novel disease genes for isolated polycystic liver disease and unsolved cases of ADPKD. Through biological investigation of her findings, she has described components in the maturation pathway of the ADPKD polycystin proteins.

Alessandra Boletta, Ph.D.Alessandra Boletta, Ph.D.

San Raffaele Scientific Institute

Investigating the Role of Mitochondrial Fitness in Polycystic Kidney Disease Progression

View summary View bio

Alessandra Boletta, Ph.D.Alessandra Boletta, Ph.D.

San Raffaele Scientific Institute

Investigating the Role of Mitochondrial Fitness in Polycystic Kidney Disease Progression

ADPKD is a slowly progressive disease, affecting approximately 1/2000 individuals worldwide. Formation and expansion of cysts in both kidneys is the hallmark of the disease. Several pathways de-regulated in the disease offering important therapeutic opportunities. Among these, we and others have reported a dysfunction in basic metabolic needs of the cell, such as glucose utilization and energy production. In preliminary studies we now found that the subcellular organelle deputed to energy production in the cell, the mitochondrion, is structurally and functionally altered. These alterations might explain the metabolic derangement observed. We aim at investigating the structural, functional and molecular details of mitochondrial alterations in the disease. Furthermore, we propose to genetically manipulate the function of mitochondria in animal models to determine whether disease initiation or progression depend on the function of this organelle.

Alessandra Boletta, Ph.D.Alessandra Boletta, Ph.D.

San Raffaele Scientific Institute

Investigating the Role of Mitochondrial Fitness in Polycystic Kidney Disease Progression

Dr. Boletta graduated in Biology at the University of Pavia, Italy. She carried out her Ph.D.-equivalent training at the Mario Negri Institute in Bergamo, Italy working on gene delivery to the kidney prior to moving to the Johns Hopkins University, Baltimore, MD for her post-doctoral training. Here, she started her scientific activity on Polycystic Kidney Disease, by working on heterologous expression of Polycystin-1 aimed at establishing cellular models to investigate its function.

Dr. Boletta moved back to Italy to establish her independent lab at the San Raffaele Scientific Institute in Milan, where today she is Head of Research Unit and Director of the Division of Genetics and Cell Biology. She uses cellular and animal models to study the pathophysiology of ADPKD. Her laboratory has identified metabolic reprogramming as an important feature of the disease, offering several new options for therapy and novel insights into the pathogenesis of ADPKD.

Paul DeCaen, Ph.D.Paul DeCaen, Ph.D.

Northwestern University

The molecular and mechanistic impacts of Finger 1 variants on PKD2 ion channel function in the primary cilia

View summary View bio

Paul DeCaen, Ph.D.Paul DeCaen, Ph.D.

Northwestern University

The molecular and mechanistic impacts of Finger 1 variants on PKD2 ion channel function in the primary cilia

Many patients with ADPKD inherit and acquire subtle mutations in the PKD2 gene, which encodes for an ion channel– a pore that controls the flow of ions across cell membranes. Yet we still do not know how mutations impact PKD2’s function because it is found in a tiny, hair-like cellular organelle called the “primary cilia”, which presents a significant challenge to study. However, our laboratory has developed state-of-the-art methodologies to assess PKD2 mutations directly from the primary cilia and their impacts on its molecular structure. Here we focus on a cluster of mutations found within “Finger 1” of PKD2 and ask– how do they alter this channels function and its atomic assembly in the cilia? Understanding the consequences of these mutations is the first step in establishing PKD2 as potential drug target for ADPKD intervention and forms the molecular basis for the initiation of cyst formation in this common disease.

Paul DeCaen, Ph.D.Paul DeCaen, Ph.D.

Northwestern University

The molecular and mechanistic impacts of Finger 1 variants on PKD2 ion channel function in the primary cilia

Dr. DeCaen earned a bachelor’s degree in Physiology from the University of California, Santa Barbara and worked as an Associate Scientist for Pfizer Research and development for five years prior to earning his Ph.D. in Pharmacology from the University of Washington. Here, he received his training in ion channel biophysics from Dr. William Catterall. Dr DeCaen received additional training as a postdoctoral fellow at Harvard Medical School under Dr. David Clapham while investigating the impact of TRP channels on cell physiology. He is a Gottschalk Research Scholar and has published more than twenty publications in journals such as Nature, PNAS, Cell, eLife and EMBO. He is currently an assistant professor at Northwestern University where his lab is focused the molecular biophysics of Polycystin channels and their signaling from the primary cilia to the cell.

Daria Ilatovskaya, Ph.D.Daria Ilatovskaya, Ph.D.

Medical University of South Carolina

Effects of dietary salt restriction on cystogenesis in ARPKD

View summary View bio

Daria Ilatovskaya, Ph.D.Daria Ilatovskaya, Ph.D.

Medical University of South Carolina

Effects of dietary salt restriction on cystogenesis in ARPKD

Autosomal recessive form of the polycystic kidney disease (ARPKD) is a genetic disorder that has an incidence of 1 in 20,000 live births; infants affected with this disorder, if they survive, develop chronic kidney failure by adolescence and eventually require kidney transplantation. ARPKD patients are advised to limit their salt intake as it is generally accepted that excessive salt consumption is harmful to people with hypertension and chronic kidney disease (CKD). However, latest data show that both excessive and insufficient salt intake might be detrimental for CKD. Currently there are no studies that would address how salt might affect ARPKD development and whether it may produce beneficial or harmful effects. This project is focused on the role of diet, and specifically its salt content, in the development of ARPKD. Anticipated results of this study will provide novel insights potentially useful for the treatment of the disease.

Daria Ilatovskaya, Ph.D.Daria Ilatovskaya, Ph.D.

Medical University of South Carolina

Effects of dietary salt restriction on cystogenesis in ARPKD

Dr. Daria Ilatovskaya is an early career investigator who has recently started an independent
laboratory at the Division of Nephrology at the Medical University of South Carolina (MUSC).
She moved to MUSC from the Medical College of Wisconsin (Department of Physiology) after
postdoctoral training and early faculty years under mentorship of Prof. Alexander Staruschenko.
Dr. Ilatovskaya studies the regulation of ion channels and transporters in polycystic kidney
disease and hypertension; her current research is funded by the NIDDK K99/R00 Career
Development Award devoted to the role of ATP in autosomal recessive PKD development. Dr.
Ilatovskaya has a long-term interest in PKD, and seeks to decipher molecular mechanisms that
underlie these complex hereditary conditions in order to pave the road to the cure using basic
science tools and models. Dr. Ilatovskaya is a passionate research advocate and an active
member of professional societies, where she is working on supporting young investigators and
trainees, and promoting kidney disease research.

Robin Maser, Ph.D.Robin Maser, Ph.D.

University of Kansas Medical Center

Mechanism of polycystin-1-regulated G protein signaling and its role in the pathogenesis and treatment of PKD

View summary View bio

Robin Maser, Ph.D.Robin Maser, Ph.D.

University of Kansas Medical Center

Mechanism of polycystin-1-regulated G protein signaling and its role in the pathogenesis and treatment of PKD

Polycystin-1 is the protein encoded by the PKD1 gene, which is responsible for the vast majority of cases of ADPKD. Polycystin-1 is a very large and complex, and is thought to perform multiple cellular functions. Recent studies have demonstrated that the modulation of cellular signaling by polycystin-1 is critical for the prevention of cystic kidney disease. However, essentially nothing is known about how this function of polycystin-1 is regulated. A number of striking similarities, both structural and functional, are shared by polycystin-1 and a group of signaling proteins called the Adhesion class of G protein-coupled receptors (GPCRs). Importantly, mechanisms that regulate signaling by the Adhesion GPCRs were recently elucidated. Our preliminary studies support the hypothesis that similar mechanisms may regulate polycystin-1 signaling. This application intends to build on our hypothesis, which if shown to be correct, will likely lead to new therapeutic approaches for the treatment of ADPKD.

Robin Maser, Ph.D.Robin Maser, Ph.D.

University of Kansas Medical Center

Mechanism of polycystin-1-regulated G protein signaling and its role in the pathogenesis and treatment of PKD

Robin Maser, Ph.D., received her doctorate from the Department of Biochemistry and Molecular Biology at The University of Kansas Medical Center (KUMC) working on the transcription and function of small nuclear RNAs. She pursued postdoctoral studies under the direction of James Calvet, also at KUMC, which focused on identifying genes that were differentially expressed in cystic kidneys of the cpk mouse model of PKD. She later joined the faculty at KUMC and continued to work on multiple aspects of cystic kidney disease, including the signaling functions of polycystin-1, and the pathogenic mechanisms and treatment of ADPKD in collaboration with James Calvet, Jared Grantham, and Vince Gattone, respectively. Research from her lab demonstrated the membrane-embedded structure and biogenesis of polycystin-1. The current project is focused on understanding the mechanism of polycystin-1 regulated G protein signaling and its potential for therapeutic targeting. When not working in the lab, Robin enjoys kayaking, pickleball, woodworking, and spending time with her furry ‘kids’ (2 labrador retrievers).

Jeremy Reiter, M.D., Ph.D.Jeremy Reiter, M.D., Ph.D.

University of California, San Francisco

Understanding how the ciliary transition zone controls Polycystin-2 localization to cilia

View summary View bio

Jeremy Reiter, M.D., Ph.D.Jeremy Reiter, M.D., Ph.D.

University of California, San Francisco

Understanding how the ciliary transition zone controls Polycystin-2 localization to cilia

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic disorders, and is a leading cause of end-stage renal disease. Total kidney volume (TKV) has become the main image-based biomarker for following ADPKD progression. This project will develop automated tools to increase measurement throughput, and explore new image-based biomarkers that will significantly add to the assessment of patient prognosis. It will also have the ability to more quickly judge the effectiveness of interventions.

Jeremy Reiter, M.D., Ph.D.Jeremy Reiter, M.D., Ph.D.

University of California, San Francisco

Understanding how the ciliary transition zone controls Polycystin-2 localization to cilia

Dr. Jeremy Reiter, MD, PhD, did his thesis work at UCSF with Dr. Didier Stainier, with whom he identified
genetic regulators of zebrafish heart and gut development. He did a postdoc with Dr. Bill Skarnes at UC
Berkeley, developing gene editing technology to explore mammalian development. The work from the
Reiter lab has contributed to the understanding of primary cilia, small antennae-like structures present
on almost all human cell types, as sensors of diverse cues. Their work has also shown that cancer cells
can be ciliated and addicted to their cilia for uncontrolled proliferation. More recently, the Reiter lab
has illuminated how the lipid and protein composition of the cilium is generated to allow it to function
as a specialized signaling organelle, and some of the ways in which altering ciliary function causes
diseases as diverse as neural tube birth defects and polycystic kidney disease. He currently serves as
chairman of the Department of Biochemistry and Biophysics at UCSF.

Adrian Salic, Ph.D.Adrian Salic, Ph.D.

Harvard University

Taking PKD out of the kidney: dissection of polycystin signaling in a novel cell-based system

View summary View bio

Adrian Salic, Ph.D.Adrian Salic, Ph.D.

Harvard University

Taking PKD out of the kidney: dissection of polycystin signaling in a novel cell-based system

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic disorders, and is a leading cause of end-stage renal disease. Total kidney volume (TKV) has become the main image-based biomarker for following ADPKD progression. This project will develop automated tools to increase measurement throughput, and explore new image-based biomarkers that will significantly add to the assessment of patient prognosis. It will also have the ability to more quickly judge the effectiveness of interventions.

Adrian Salic, Ph.D.Adrian Salic, Ph.D.

Harvard University

Taking PKD out of the kidney: dissection of polycystin signaling in a novel cell-based system

Adrian Salic is Professor of Cell Biology at Harvard Medical School. His lab focuses on two main directions: 1) Understanding the molecular mechanisms involved in cell-cell signaling through the various pathways critical during embryonic development and in disease; and 2) Developing novel chemical probes for microscopic imaging and functional assays of various biological molecules (nucleic acids, proteins, lipids), in cells and in animals.

John Shine, Ph.D.John Shine, Ph.D.

Garvan Institute

Understanding the role of somatic variation and novel mutational mechanisms in the genetic pathogenesis of PKD

View summary View bio

John Shine, Ph.D.John Shine, Ph.D.

Garvan Institute

Understanding the role of somatic variation and novel mutational mechanisms in the genetic pathogenesis of PKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic kidney disorder it causes cysts to develop within the kidney, which eventually destroy the normal kidney tissue and lead to renal failure in many patients. Despite how common the disease is there are still many gaps in our understanding. There are still many families in which we cannot identify the genetic cause of their disease and there remain many questions about the reason kidney cysts develop and destroy the kidney. Our project will use the latest in genomic sequencing technologies to identify new genetic causes of ADPKD and to try and identify unique mutations in individual kidney cysts that may be causing disease. Understanding these mechanisms will help to develop ways to slow and treat ADPKD.

John Shine, Ph.D.John Shine, Ph.D.

Garvan Institute

Understanding the role of somatic variation and novel mutational mechanisms in the genetic pathogenesis of PKD

Professor Shine was Executive Director of the Garvan Institute of Medical Research from 1990 until 2011 and remains at the Institute as an Emeritus Professor. He is also Professor of Medicine and Professor of Molecular Biology at the University of NSW. He was Chairman of the National Health and Medical Research Council from 2003 – 2006, and is President of the Australian Academy of Science. He is a Companion in the Order of Australia and until 2011 was a Member of the Prime Minister’s Science, Engineering and Innovation Council. In 2010 he received the nation’s highest award for science – the Prime Minister’s Prize for Science.

Oliver Wessely, Ph.D.Oliver Wessely, Ph.D.

Cleveland Clinic/Case Western Reserve University

Regulation of Ciliary G-Protein Signaling by Polycystin-1

View summary View bio

Oliver Wessely, Ph.D.Oliver Wessely, Ph.D.

Cleveland Clinic/Case Western Reserve University

Regulation of Ciliary G-Protein Signaling by Polycystin-1

Polycystic Kidney Diseases are abundant genetic disorders characterized by the formation of fluid-filled cysts in the kidney. A large percentage of the patients carry mutations in Polycystin-1, a large transmembrane protein with similarities to G-protein-coupled receptors. These cell surface proteins regulates many processes in the body. Preliminary data demonstrate that a part of Polycystin-1 regulates the activity of other G-protein-coupled receptor in the vicinity by competing for shared signaling partners. This project will explore how this crosstalk impacts the function of cilia, small, hair-like organelles, which line the surface of cells and are critically important in Polycystic Kidney Disease. Using tools that allow us to specifically assess and manipulate the processes in the cilia we will investigate the cellular and kidney-wide effects of the crosstalk between Polycystin-1 and other G-protein-coupled receptors. This study will provide new insides into Polycystin-1 and how this can be harnessed for novel therapeutic interventions.

Oliver Wessely, Ph.D.Oliver Wessely, Ph.D.

Cleveland Clinic/Case Western Reserve University

Regulation of Ciliary G-Protein Signaling by Polycystin-1

Dr. Oliver Wessely obtained his Ph.D. from the University of Vienna in Austria. After a postdoctoral fellowship at UCLA/HHMI and a faculty position at the LSU Health Sciences Center in New Orleans, he is currently Associate Staff in the Department of Cell Biology in the Lerner Research Institute of Cleveland Clinic. His research is centered on general principles of kidney development and their perturbation during disease formation with a focus on Polycystic Kidney Disease.

Laurel Willig, M.D.Laurel Willig, M.D.

Children’s Mercy

Molecular Characterization of Cyst Formation in a Porcine Model of Early ADPKD

View summary View bio

Laurel Willig, M.D.Laurel Willig, M.D.

Children’s Mercy

Molecular Characterization of Cyst Formation in a Porcine Model of Early ADPKD

Polycystic Kidney Diseases are abundant genetic disorders characterized by the formation of fluid-filled cysts in the kidney. A large percentage of the patients carry mutations in Polycystin-1, a large transmembrane protein with similarities to G-protein-coupled receptors. These cell surface proteins regulates many processes in the body. Preliminary data demonstrate that a part of Polycystin-1 regulates the activity of other G-protein-coupled receptor in the vicinity by competing for shared signaling partners. This project will explore how this crosstalk impacts the function of cilia, small, hair-like organelles, which line the surface of cells and are critically important in Polycystic Kidney Disease. Using tools that allow us to specifically assess and manipulate the processes in the cilia we will investigate the cellular and kidney-wide effects of the crosstalk between Polycystin-1 and other G-protein-coupled receptors. This study will provide new insides into Polycystin-1 and how this can be harnessed for novel therapeutic interventions.

Laurel Willig, M.D.Laurel Willig, M.D.

Children’s Mercy

Molecular Characterization of Cyst Formation in a Porcine Model of Early ADPKD

Dr. Willig is a pediatric nephrologist at Children’s Mercy Hospital-Kansas City. She has a master’s degree
in genetic epidemiology. She has a special research interest in genomic applications in clinical medicine.
Her work in newborn populations is one of the first reports of rapid whole genome sequencing in
acutely ill neonates. She has also done work in renal systems biology in adults with systemic
inflammatory response syndrome. She currently is the site principle investigator for the NIH funded
grant “Early-Stage Polycystic Kidney Disease Biomarkers Repository Study”. Her current research
interests involve examining how genomics and epigenomics influence early cyst initiation in polycystic
kidney disease. In addition to her research interests, Dr. Willig is an active clinician educator who has
given many educational lectures in the Department of Pediatrics and mentored both nephrology fellows
and pediatric residents in research projects. Through her role as the Medical Director of the Center for
Pediatric Genomic Medicine (CPGM), she is active in educating hospital staff in genomic applications in
their research and organizing the research program of the CPGM.

Owen Woodward, Ph.D.Owen Woodward, Ph.D.

University of Maryland

Disruption of the Apical Junctional Complex in Cystogenesis and ADPKD

View summary View bio

Owen Woodward, Ph.D.Owen Woodward, Ph.D.

University of Maryland

Disruption of the Apical Junctional Complex in Cystogenesis and ADPKD

Inheritance of polycystic kidney disease genes causes slow growing kidney cysts with severe consequences for kidney function. Study of disease causation is often obscured by the later stages of a multistage disease process. Here we focus on the first stage of ADPKD, cystogenesis, and propose experiments focused solely on the first protein changes that occur upon acute loss of the PKD2 disease gene and protein product PC2. Using a new ex-vivo 3D culture method to grow epithelial kidney tubes in the lab, we will investigate what happens to the junctions between the cells of the tubes as they transform into cysts with the loss of PKD2. Discovery of the initial steps of cystogenesis after PKD2 loss may illuminate precise drugable targets for the development of future PKD therapeutics.

Owen Woodward, Ph.D.Owen Woodward, Ph.D.

University of Maryland

Disruption of the Apical Junctional Complex in Cystogenesis and ADPKD

I was born and grew up in Virginia and graduated from the University of Virginia. I received my PhD from the University of Washington, in Seattle, and did by my post-doctoral Fellowship training in the Department of Physiology at the Johns Hopkins University School of Medicine. I joined the Faculty in Physiology at the University of Maryland School of Medicine in 2015 as an Assistant Professor and soon after joined the Baltimore PKD Research and Clinical Core Center as a Co-Director for the Cell Culture and Engineering Core. The one central theme through my training and current work is a desire to better understand the cell and molecular physiology of epithelial cells, how the various channels and transporters function to determine the physiology of the kidney and, ultimately, individuals. We have used this approach in our work to better understand Polycystic Kidney Disease, focusing on the acute cell biological changes that occur with the loss of the PKD genes in renal epithelia cells during the early stages of cystogenesis. When not thinking about cysts, I enjoy hiking and playing soccer with my family.

Yong Yu, Ph.D.Yong Yu, Ph.D.

St. John’s University

The role of polycystin-1 in the polycystin-1/polycystin-2 ion channel complex

View summary View bio

Yong Yu, Ph.D.Yong Yu, Ph.D.

St. John’s University

The role of polycystin-1 in the polycystin-1/polycystin-2 ion channel complex

ADPKD is caused by mutations in two cell membrane proteins polycystin-1 (PC1) and polycystin-2 (PC2). These two proteins form a complex and function together to mediate cell signaling. PC2 is an ion channel protein in the complex which controls the flow of ions across the cell membrane, while the function of PC1 is largely unknown. This study will allow us to achieve a molecular understanding of the role of PC1 in the PC1/PC2 complex and how the function of this complex is regulated.

Yong Yu, Ph.D.Yong Yu, Ph.D.

St. John’s University

The role of polycystin-1 in the polycystin-1/polycystin-2 ion channel complex

Dr. Yong Yu received his Ph.D. in Biochemistry and Biophysics from the Shanghai Institute of Plant
Physiology and Ecology, Chinese Academy of Sciences in 2001. He had his postdoc training first at the
Center for Molecular Recognition at Columbia University with Dr. Arthur Karlin, then at the Department
of Biological Sciences at Columbia University with Dr. Jian Yang. After working at Columbia University as
Associate Research Scientist, he joined St. John’s University as an Assistant Professor in 2012 and was
promoted to Associate Professor with tenure in 2016. Dr. Yu’s research has been focused on the
molecular mechanism of the assembly and function of the polycystin proteins with combined
biochemistry, biophysics, electrophysiology, and crystallography approaches.

Xiaogang Li, Ph.D.Xiaogang Li, Ph.D.

Mayo Clinic

The roles of DNA methylation in autosomal dominant polycystic kidney disease

View summary View bio

Xiaogang Li, Ph.D.Xiaogang Li, Ph.D.

Mayo Clinic

The roles of DNA methylation in autosomal dominant polycystic kidney disease

In this study, we will identify aberrant DNA methylation signatures associated with ADPKD and investigate the functional roles and the underling mechanisms of DNA methyltransferase, DNMT1, in regulating cyst progression, and will test whether de-methylation of hypermethylated DNA mediated by DNMT1 delays cyst growth in vivo. In particular, we will use whole-genome bisulfite sequencing (WGBS) to examine the DNA methylation profiles of normal human and ADPKD kidney samples. We will also identify novel DNMT1 target genes in regulating renal epithelial cell proliferation, apoptosis and ciliopathy during cyst development. Our study will identify the methylation of specific genes in PKD associated signaling pathways and in pathways not previously studied in PKD, which should forward our understanding about the roles of DNA methylation in ADPKD progression. Accomplishing this project will lead to a better understanding of the mechanism of renal cyst formation and will provide novel therapeutic targets for ADPKD treatment.

Xiaogang Li, Ph.D.Xiaogang Li, Ph.D.

Mayo Clinic

The roles of DNA methylation in autosomal dominant polycystic kidney disease

Xiaogang Li, PhD, Professor of Medicine at Mayo Clinic and Honorary Investigator of Mayo
Translational PKD Center. He is also a professor of Biochemistry and Molecular Biology at
Mayo. His research encompasses both basic science and translational aspects of PKD. In
particular, he is widely regarded as one of the world’s foremost authorities on epigenetics and
renal inflammation in PKD. Furthermore, he re-evaluates the roles of apoptosis in autosomal
dominant PKD, contributing to a better understanding of the mechanisms of this disease. He
has published extensively in the field including publications in Nature Cell Biology, Nature
Medicine, and Journal of Clinical Investigation. His studies are leading to the use of promising
new therapeutic drugs in PKD treatment. In addition, he served as the editor of a book entitled
“Polycystic Kidney Disease” (2015), which was the first PKD book on NIH bookshelf.

Karel Liem, M.D., Ph.D.Karel Liem, M.D., Ph.D.

Yale University

Role of interstitial cells in renal cystogenesis

View summary View bio

Karel Liem, M.D., Ph.D.Karel Liem, M.D., Ph.D.

Yale University

Role of interstitial cells in renal cystogenesis

Cystic Renal diseases are among the most common human genetic diseases and are associated with the formation of fluid-filled renal cysts composed of epithelial cells, that compromise kidney function. These forms of renal diseases affect both children and adults and is the leading genetic cause end stage kidney disease and is thus a major public health challenge. We have identified a different population of kidney cells, the interstitial cells, that is involved with the initiation/progression of the disease and propose experiments to better understand the cellular and molecular processes by which cysts develop. There is currently no effective pharmacological treatment for cystic diseases and these studies will identify the molecular and cellular signaling pathways associated with initiation of the disease, which will may lead to identifying possible therapeutic targets.

Karel Liem, M.D., Ph.D.Karel Liem, M.D., Ph.D.

Yale University

Role of interstitial cells in renal cystogenesis

Karel F. Liem Jr. is a developmental biologist. He graduated from Harvard College with a B.A. in Biology and obtained the MD and PhD degrees from Columbia University College of Physicians and Surgeons. He has trained at the Sloan Kettering Institute, University College London and Harvard University. He is currently an Assistant Professor at Yale School of Medicine. The Liem lab uses genetic techniques in the mouse to identify genes and molecular pathways important for embryonic development and disease.

Meet our past grant recipients